Prokidney

Prokidney Working Capital Turnover

Working Capital Turnover of Prokidney (PROK) as of Nov 15, 2026.

Working Capital Turnover

0.00

Last updated:

Working Capital Turnover of Prokidney is 2025 0.00 . Working Capital Turnover of Prokidney was 2024 0.00 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prokidney Stock analysis

What does Prokidney do? Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease. Prokidney is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prokidney stock

On Eulerpool you can find the complete historical development of Working Capital Turnover Prokidney since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Prokidney with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Prokidney

All Key Metrics — Prokidney